Proof-of-concept trial of NLX 112 (befiradol) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease.

Trial Profile

Proof-of-concept trial of NLX 112 (befiradol) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease.

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2014

At a glance

  • Drugs Befiradol (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Neurolixis
  • Most Recent Events

    • 08 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top